Mesoblast Completes Treatment in Phase 3 Low Back Pain Trial
New York, USA / Melbourne, Australia August 17, 2026: Mesoblast Limited has completed patient treatment in its pivotal Phase...
Mesoblast
Advertisement
Mesoblast Strengthens Cell Therapy Portfolio with RYONCIL Growth and FDA Progress
NEW YORK, USA / MELBOURNE, Australia, July 29–30, 2026 Mesoblast Limited reported strong commercial and clinical progress for the...
Mesoblast Completes Enrollment in Low Back Pain Trial
NEW YORK and MELBOURNE, July 13-14, 2026 Mesoblast Limited announced that it has achieved its target of treating at...
Mesoblast Receives FDA BLA Filing Number for Rexlemestrocel-L
New York, USA & Melbourne, Australia, July 1, 2026 Mesoblast Limited announced that the U.S. Food and Drug Administration...
Mesoblast Completes Enrollment in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, USA & MELBOURNE, Australia, April 28–29, 2026 Mesoblast Limited has announced that it has achieved the patient...
Advertisement
